on Newron Pharmaceuticals S.p.A. (isin : IT0004147952)
Newron and EA Pharma Sign License Agreement for Evenamide in Asia
Newron Pharmaceuticals S.p.A. has signed a license agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture, and commercialize evenamide in Japan and other Asian territories. Newron will be eligible to receive up to €117 million from EA Pharma. This includes an upfront payment of €44 million, alongside development and commercialization milestones, plus tiered royalties on net sales.
Evenamide, a treatment for treatment-resistant schizophrenia, targets the excessive release of glutamate. Newron plans to start a Phase III trial in the first half of 2025. The agreement is set to significantly impact Newron's 2024 financial results. Stefan Weber, CEO of Newron, emphasized the significance of this milestone to offer innovative alternatives to patients with schizophrenia.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Newron Pharmaceuticals S.p.A. news